IRIS
DELLA CORTE, Carminia Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.016
AS - Asia 2.609
NA - Nord America 2.077
SA - Sud America 372
AF - Africa 35
OC - Oceania 5
Totale 12.114
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.079
US - Stati Uniti d'America 2.006
SG - Singapore 994
IE - Irlanda 626
IT - Italia 557
HK - Hong Kong 498
CN - Cina 481
BR - Brasile 318
DE - Germania 217
KR - Corea 178
VN - Vietnam 167
GB - Regno Unito 124
FR - Francia 103
IN - India 80
UA - Ucraina 74
JP - Giappone 70
FI - Finlandia 61
CA - Canada 37
AT - Austria 36
GR - Grecia 34
NL - Olanda 27
TR - Turchia 25
BD - Bangladesh 22
MX - Messico 20
PK - Pakistan 19
SE - Svezia 19
AR - Argentina 18
ID - Indonesia 16
EC - Ecuador 12
IQ - Iraq 11
CL - Cile 10
CZ - Repubblica Ceca 10
PL - Polonia 10
ZA - Sudafrica 10
BE - Belgio 9
ES - Italia 8
AE - Emirati Arabi Uniti 7
PY - Paraguay 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 5
MA - Marocco 5
CO - Colombia 4
HU - Ungheria 4
KG - Kirghizistan 4
TN - Tunisia 4
AO - Angola 3
CH - Svizzera 3
IR - Iran 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AM - Armenia 2
AU - Australia 2
DZ - Algeria 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
MY - Malesia 1
PS - Palestinian Territory 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
VE - Venezuela 1
Totale 12.114
Salva come PNG Salva come JPEG
Città #
Moscow 1.839
Dublin 618
Hong Kong 497
Singapore 454
Santa Clara 364
Chandler 285
Seoul 178
Naples 157
Jacksonville 138
Dallas 108
Beijing 100
Ashburn 93
Hefei 92
Munich 86
New York 83
Princeton 71
Roxbury 70
Ho Chi Minh City 62
Bremen 60
The Dalles 59
Bengaluru 55
Medford 36
Turku 36
Cambridge 35
Caserta 35
Hanoi 31
São Paulo 29
Nuremberg 26
Wilmington 24
Los Angeles 22
Dong Ket 20
Boardman 19
Elora 18
Vienna 18
Napoli 17
Des Moines 16
Ann Arbor 15
Rome 13
Amsterdam 12
Milan 12
Afragola 11
Brooklyn 10
Council Bluffs 10
Da Nang 10
Falkenstein 10
Belo Horizonte 9
Brussels 9
Columbus 9
Ercolano 9
Haiphong 9
Tokyo 9
Aversa 8
Brno 8
Lappeenranta 8
London 8
Piscataway 8
Pozzuoli 8
Rio de Janeiro 8
Dhaka 7
Florence 7
Guangzhou 7
Istanbul 7
Jakarta 7
Rawalpindi 7
San Francisco 7
Toronto 7
Warsaw 7
Baku 6
Boston 6
Brasília 6
Phoenix 6
San Mateo 6
Shanghai 6
Venice 6
Viterbo 6
Woodbridge 6
Bahawalpur 5
Battipaglia 5
Campinas 5
Guayaquil 5
Helsinki 5
Nanjing 5
Porto Alegre 5
Somma Vesuviana 5
Sorocaba 5
Acerra 4
Anantapur 4
Asunción 4
Bishkek 4
Chicago 4
Giugliano in Campania 4
Guarulhos 4
Manchester 4
Mountain View 4
Norwalk 4
Paris 4
Santiago 4
Seattle 4
Stockholm 4
Zhengzhou 4
Totale 6.286
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 196
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 186
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 173
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 171
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 165
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 164
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 161
Immunotherapy for head and neck cancer: Present and future 149
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 149
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 146
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 144
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 144
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 144
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 139
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 138
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 135
Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy 135
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 135
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 134
The use of ultrasound in the evaluation of postoperative pneumothorax and lung re-expansion in patients after lung resection 132
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 131
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 131
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 126
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 126
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 125
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 124
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 124
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 124
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 124
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 124
AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors 123
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 121
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 120
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 120
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 119
Diagnosis of malignant pleural disease: Ultrasound as "a detective probe" 119
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 119
Ventilation challenge in rigid bronchoscopy: Laser tube as an alternative management in patients with lung cancer and central airway obstruction 119
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 117
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 117
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 117
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 116
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 116
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 115
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs 115
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 115
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 114
Translational insights and new therapeutic perspectives in head and neck tumors 113
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 112
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 112
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 112
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 111
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era 111
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 110
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 109
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 106
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 105
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors 105
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 104
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 104
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 103
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 101
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 100
Primary pleural squamous cell carcinoma: A diagnostic challenge 98
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma 98
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 97
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 96
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 96
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 96
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 95
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 94
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 93
Implication of the Hedgehog pathway in hepatocellular carcinoma. 92
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 92
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 91
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 91
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 91
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 90
Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives 90
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 89
PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype 88
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC 87
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 86
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 86
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy? 85
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy 85
Functional effect of adiponectin and body composition assessment in lung cancer subjects after video-assisted thoracoscopic surgery (VATS) lobectomy 85
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 84
Role of HGF-MET signaling in primary and acquired resistance to targeted therapies in cancer 84
Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers 84
Unleashing precision: A review of targeted approaches in pleural mesothelioma 84
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer 83
Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 82
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 81
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer 79
Application of Telepathology for Rapid On-Site Evaluation of Touch Imprint Cytology in CT-Guided Percutaneous Transthoracic Core Needle Biopsy of Pulmonary Nodules: The Experience of Our Multidisciplinary Thoracic Tumor Board 79
Early use of steroids affects immune cells and impairs immunotherapy efficacy 78
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 77
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients 77
Role and targeting of anaplastic lymphoma kinase in cancer 76
Totale 11.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021158 0 0 0 0 0 6 39 19 15 16 37 26
2021/2022501 9 7 9 9 110 10 44 18 26 37 67 155
2022/20231.193 114 30 25 114 127 92 12 58 558 13 29 21
2023/2024612 61 25 24 30 170 80 20 24 11 17 53 97
2024/20252.183 26 51 22 56 307 277 267 199 333 318 166 161
2025/20267.198 396 455 439 360 774 4.774 0 0 0 0 0 0
Totale 12.379